Characterization and Early Assays Development in FOXG1 Deficient Neurons
Characterization and Early Assays Development in FOXG1 Deficient Neurons
批准号:
10727503
负责人:
JED L HUBBS
金额:
$17.7万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-01 至 2024-08-31
关键词:
Biological AssayBostonCRISPR/Cas technologyCell Differentiation processCell LineCellsClinicalDevelopmentDevelopmental Delay DisordersDiseaseDyesEthicsFluorescent DyesFutureGene ProteinsGenesGeneticGenotypeGoalsHeterozygoteImageIndividualInterneuronsLigandsMeasuresMethodsMicrocephalyMovementMuscle hypotoniaMutationNeurodevelopmental DisorderNeurologic SymptomsNeuronsParentsPathway interactionsPatientsPediatric HospitalsPharmaceutical PreparationsPharmacotherapyPluripotent Stem CellsProtein DeficiencyProteinsReporterReporter GenesReportingResearchSeizuresSomatic CellStereotypingSymptomsSyndromeSystemTelencephalonValidationWorkassay developmentdrug discoverygene therapygenomic locusinduced pluripotent stem cellinterestmutantnerve stem cellnervous system disorderpostnatal developmentpre-clinicalprogramsprotein expressionscreeningsevere intellectual disabilitysmall moleculesmall molecule therapeuticsstem cell proliferationsymptomatic improvementtherapeutic developmenttherapy developmenttranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
FOXG1 syndrome is a rare neurological disorder that often causes severe intellectual disability,
microcephaly and neurological symptoms including hypotonia, seizures, and stereotypic
movements. FOXG1 syndrome is caused by heterozygous mutation or deletion of the forkhead
box 1 protein (FOXG1), a transcription factor that controls expression of key cortical development
proteins. FOXG1 is specifically important for telencephalon neural progenitor cell (NPC)
proliferation and differentiation to GABAergic interneurons. We have prioritized FOXG1 syndrome
based on a framework we developed to evaluate monogenetic neurodevelopmental disorders for
therapeutic development based on generic, preclinical validation, clinical and ethical
considerations. We have also created three pluripotent stem cell (PSC) lines from FOXG1
syndrome patients and used CRISPR/Cas9 gene editing to create isogenic control lines. We
hypothesize that a drug-like small molecule that increases FOXG1 expression in patients during
early postnatal development would improve symptoms in these individuals. In the proposed
research, we will use FOXG1 PSC lines to create an endogenous locus gene reporter line by
using CRISPR/Cas9 to insert a HaloTag reporter protein at the C-terminus of the FOXG1 gene.
A method will be developed whereby these modified FOXG1 PSCs with be differentiated to
cortical neural progenitor cells (NPCs) and treated with HaloTag ligand tethered dyes to measure
accurately measure FOXG1 expression. The primary goal of this project will be to demonstrate
that this FOXG1 reporter system is suitable for screening small molecules for their ability to
increase FOXG1 expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Direct Catalytic Asymmetric Aldol Reaction
-
批准号:6655101
-
项目类别:
-
资助金额:$3.85万
-
财政年份:2002
-
负责人:JED L HUBBS
-
依托单位:
Direct Catalytic Asymmetric Aldol Reaction
-
批准号:6550584
-
项目类别:
-
资助金额:$3.66万
-
财政年份:2002
-
负责人:JED L HUBBS
-
依托单位:
国内基金
海外基金
αβ珠蛋白融合基因—Lepore-Boston的结构及表达调控
-
批准号:39370398
-
项目类别:面上项目
-
资助金额:7.0万元
-
批准年份:1993
-
负责人:朱定尔
-
依托单位: